Published in Front Oncol on April 29, 2013
Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature (1996) 18.47
Vascular endothelial growth factor is a secreted angiogenic mitogen. Science (1989) 16.71
Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell (2009) 16.06
Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer (2008) 15.20
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell (2007) 12.52
VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol (2006) 12.09
Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev (2004) 11.69
Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature (1992) 10.10
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell (2005) 9.18
Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol (2008) 8.79
Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology (2008) 8.10
HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell (2008) 8.01
Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med (2011) 7.37
Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA (2008) 7.13
Glioblastoma stem-like cells give rise to tumour endothelium. Nature (2010) 6.18
Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature (2010) 6.13
A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1alpha regulates the VEGF expression and is potentially involved in lung and vascular development. Proc Natl Acad Sci U S A (1997) 6.11
Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes. Nat Med (2006) 5.22
Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis. Genes Dev (2002) 5.15
Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem (1992) 4.92
Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res (1995) 4.84
PDGFRbeta+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat Cell Biol (2005) 4.57
Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol (2005) 4.03
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst (2007) 3.95
Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med (2009) 3.85
Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest (2010) 3.74
Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin. J Biol Chem (1994) 3.68
Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology (2009) 3.68
Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol (2010) 3.67
Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci U S A (2011) 3.48
FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist (2009) 3.18
Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol (2008) 3.00
Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J Neurosurg (2009) 2.66
Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology (2009) 2.55
Regulation of vascular endothelial growth factor by the Wnt and K-ras pathways in colonic neoplasia. Cancer Res (2001) 2.47
Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer Res (2011) 2.40
Effect of bevacizumab on radiation necrosis of the brain. Int J Radiat Oncol Biol Phys (2007) 2.10
Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol (2008) 2.06
FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist (2007) 1.94
Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br J Cancer (2009) 1.78
Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptor-selective VEGF variants by site-directed mutagenesis. J Biol Chem (1996) 1.73
Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape. Cancer Res (2011) 1.69
Both v-Ha-Ras and v-Raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells. J Biol Chem (1995) 1.65
Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib. Cancer Res (2010) 1.58
Reversible skeletal changes after treatment with bevacizumab in a child with cutaneovisceral angiomatosis with thrombocytopenia syndrome. Pediatr Blood Cancer (2008) 1.54
A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma. J Neurosurg (2011) 1.52
Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. J Clin Oncol (2010) 1.50
Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. J Neurooncol (2012) 1.42
Pediatric brain tumors: current treatment strategies and future therapeutic approaches. Neurotherapeutics (2009) 1.40
FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. Oncologist (2007) 1.38
Advances in MRI assessment of gliomas and response to anti-VEGF therapy. Curr Neurol Neurosci Rep (2011) 1.34
Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma. J Neurooncol (2003) 1.30
Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan. Pediatr Blood Cancer (2009) 1.29
Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2. Neuro Oncol (2009) 1.28
Angiogenic heterogeneity: regulation of neoplastic angiogenesis by the organ microenvironment. J Natl Cancer Inst (2001) 1.28
Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors. Cancer (2008) 1.27
Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer. J Clin Endocrinol Metab (2010) 1.26
The cause of death in patients with glioblastoma is multifactorial: clinical factors and autopsy findings in 117 cases of supratentorial glioblastoma in adults. J Neurooncol (1991) 1.20
Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents. Cancer Res (2009) 1.20
Bevacizumab as a treatment option for radiation-induced cerebral necrosis. Strahlenther Onkol (2011) 1.20
3'-deoxy-3'-18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab. J Nucl Med (2011) 1.18
Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab. Neuro Oncol (2011) 1.17
Serial magnetic resonance spectroscopy reveals a direct metabolic effect of cediranib in glioblastoma. Cancer Res (2011) 1.13
Transdifferentiation of glioblastoma stem-like cells into mural cells drives vasculogenic mimicry in glioblastomas. J Neurosci (2012) 1.10
Immunohistochemical markers for prognosis of ependymal neoplasms. J Neurooncol (2002) 1.09
Bevacizumab as therapy for radiation necrosis in four children with pontine gliomas. Int J Radiat Oncol Biol Phys (2009) 1.06
Bevacizumab reverses cerebral radiation necrosis. J Clin Oncol (2008) 1.05
Weekly vinblastine in pediatric low-grade glioma patients with carboplatin allergic reaction. Cancer (2005) 1.05
Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas. Pediatr Blood Cancer (2012) 1.03
Compassionate use of bevacizumab (Avastin) in children and young adults with refractory or recurrent solid tumors. Ann Oncol (2007) 1.02
Positron emission tomography imaging of cancer biology: current status and future prospects. Semin Oncol (2011) 1.02
Change in pattern of relapse after antiangiogenic therapy in high-grade glioma. Int J Radiat Oncol Biol Phys (2010) 0.97
Rapid improvement of life-threatening capillary leak syndrome after stem cell transplantation by bevacizumab. Blood (2010) 0.96
Bevacizumab in recurrent high-grade pediatric gliomas. Neuro Oncol (2010) 0.96
Glioma stem/progenitor cells contribute to neovascularization via transdifferentiation. Stem Cell Rev (2011) 0.96
Angiogenic profile of childhood primitive neuroectodermal brain tumours/medulloblastomas. Eur J Cancer (2001) 0.96
Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma--a Pediatric Brain Tumor Consortium study. Neuro Oncol (2012) 0.92
Role of vascular endothelial growth factor-A in recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol (2005) 0.91
First report of effective and feasible treatment of multifocal lymphangiomatosis (Gorham-Stout) with bevacizumab in a child. Ann Oncol (2010) 0.90
Bilateral response after unilateral subconjunctival bevacizumab injection in a child with Stevens-Johnson syndrome. J AAPOS (2012) 0.90
Bevacizumab: a treatment option for recurrent glioblastoma multiforme. Ann Pharmacother (2008) 0.90
Vascular endothelial growth factor (VEGF) in astrocytic gliomas--a prognostic factor? J Neurooncol (1999) 0.90
Feasibility and tolerability of bevacizumab in children with primary CNS tumors. Pediatr Blood Cancer (2010) 0.88
Thalidomide as an anti-angiogenic agent in relapsed gliomas. J Neurooncol (2001) 0.87
Bevacizumab and irinotecan in children with recurrent or refractory brain tumors: toxicity and efficacy trends. Pediatr Blood Cancer (2012) 0.87
Bevacizumab and irinotecan in the treatment of children with recurrent/refractory medulloblastoma. Pediatr Blood Cancer (2011) 0.86
Bevacizumab for the treatment of pediatric retinal and choroidal diseases. Ophthalmic Surg Lasers Imaging (2010) 0.85
Hemodynamic response imaging: a potential tool for the assessment of angiogenesis in brain tumors. PLoS One (2012) 0.85
Treatment of children with recurrent high grade gliomas with a bevacizumab containing regimen. J Neurooncol (2010) 0.83
Comprehensive management of bilateral acoustic neuromas. Current perspectives. Arch Otolaryngol Head Neck Surg (1994) 0.83
Antiangiogenic treatment as a pre-operative management of alveolar soft-part sarcoma. Pediatr Blood Cancer (2011) 0.81
Vascular endothelial growth factor (VEGF) receptor antibody bevacizumab (avastin) induces regression of renal cell carcinoma in an adolescent resulting in residual tumorectomy. Pediatr Blood Cancer (2008) 0.79
A phase II trial of thalidomide and cyclophosphamide in patients with recurrent or refractory pediatric malignancies. Pediatr Blood Cancer (2007) 0.76
Bevacizumab treatment in multifocal lymphangioendotheliomatosis with thrombocytopenia. Pediatr Blood Cancer (2009) 0.76
Use of 532-nm pulsed potassium titanyl phosphate laser and adjuvant intralesional bevacizumab for aggressive respiratory papillomatosis in children: initial experience. Arch Otolaryngol Head Neck Surg (2010) 0.76
Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature (2012) 4.13
Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood (2008) 3.67
Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1. Ann Neurol (2014) 3.01
A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J Pediatr Hematol Oncol (2005) 2.14
Targeted inhibition of cyclic AMP phosphodiesterase-4 promotes brain tumor regression. Clin Cancer Res (2008) 1.75
Spatiotemporal differences in CXCL12 expression and cyclic AMP underlie the unique pattern of optic glioma growth in neurofibromatosis type 1. Cancer Res (2007) 1.69
Widespread CXCR4 activation in astrocytomas revealed by phospho-CXCR4-specific antibodies. Cancer Res (2005) 1.62
Pathological expression of CXCL12 at the blood-brain barrier correlates with severity of multiple sclerosis. Am J Pathol (2008) 1.58
Cytogenetic prognostication within medulloblastoma subgroups. J Clin Oncol (2014) 1.56
Preclinical cancer therapy in a mouse model of neurofibromatosis-1 optic glioma. Cancer Res (2008) 1.47
Blocking CXCR4-mediated cyclic AMP suppression inhibits brain tumor growth in vivo. Cancer Res (2007) 1.44
Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J Clin Oncol (2013) 1.43
TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathol (2013) 1.35
Immune and nervous system CXCL12 and CXCR4: parallel roles in patterning and plasticity. Trends Immunol (2004) 1.27
Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1. Cancer Res (2010) 1.20
Glioblastoma in children: a single-institution experience. Int J Radiat Oncol Biol Phys (2011) 1.16
Successful antiangiogenic therapy of giant cell angioblastoma with interferon alfa 2b: report of 2 cases. Pediatrics (2002) 1.12
Morphine increases brain levels of ferritin heavy chain leading to inhibition of CXCR4-mediated survival signaling in neurons. J Neurosci (2009) 1.10
CXCR4 activation defines a new subgroup of Sonic hedgehog-driven medulloblastoma. Cancer Res (2011) 1.09
Feasibility of small animal cranial irradiation with the microRT system. Med Phys (2008) 1.06
Treating brain tumors with PDE4 inhibitors. Trends Pharmacol Sci (2011) 1.05
Astrocyte TNFR2 is required for CXCL12-mediated regulation of oligodendrocyte progenitor proliferation and differentiation within the adult CNS. Acta Neuropathol (2012) 1.05
An integrative view on sex differences in brain tumors. Cell Mol Life Sci (2015) 1.04
Perfusion MRI of U87 brain tumors in a mouse model. Magn Reson Med (2004) 1.03
A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer. Pediatr Blood Cancer (2013) 1.01
Radiation therapy for pilocytic astrocytomas of childhood. Int J Radiat Oncol Biol Phys (2010) 0.93
Suppression of G-protein-coupled receptor kinase 3 expression is a feature of classical GBM that is required for maximal growth. Mol Cancer Res (2011) 0.92
Why does Jack, and not Jill, break his crown? Sex disparity in brain tumors. Biol Sex Differ (2012) 0.90
F11R is a novel monocyte prognostic biomarker for malignant glioma. PLoS One (2013) 0.87
CXCL12 mediates trophic interactions between endothelial and tumor cells in glioblastoma. PLoS One (2012) 0.87
Postoperative imaging surveillance in pediatric pilocytic astrocytomas. J Neurosurg Pediatr (2010) 0.86
Sexually dimorphic RB inactivation underlies mesenchymal glioblastoma prevalence in males. J Clin Invest (2014) 0.84
Brainstem glioma presenting as pruritus in children with neurofibromatosis-1. J Pediatr Hematol Oncol (2009) 0.84
Oligodendrogliomas in children. J Neurooncol (2011) 0.82
Rethinking brain tumors: the fourth Mouse Models of Human Cancers Consortium nervous system tumors workshop. Cancer Res (2008) 0.82
Growth factor receptor-Src-mediated suppression of GRK6 dysregulates CXCR4 signaling and promotes medulloblastoma migration. Mol Cancer (2013) 0.81
CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice. J Neuroimmunol (2010) 0.81
Hitting Them Where They Live: Targeting the Glioblastoma Perivascular Stem Cell Niche. Curr Pathobiol Rep (2013) 0.81
WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma. Acta Neuropathol Commun (2014) 0.79
Use of thalidomide to diminish growth velocity in a life-threatening congenital intracranial hemangioma. J Neurosurg Pediatr (2008) 0.77
Reply: To PMID 24375753. Ann Neurol (2014) 0.77
Highlights from the latest articles in glioma immunotherapy. Immunotherapy (2010) 0.75